BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 20103666)

  • 1. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors.
    Binderup T; Knigge U; Loft A; Federspiel B; Kjaer A
    Clin Cancer Res; 2010 Feb; 16(3):978-85. PubMed ID: 20103666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
    Bahri H; Laurence L; Edeline J; Leghzali H; Devillers A; Raoul JL; Cuggia M; Mesbah H; Clement B; Boucher E; Garin E
    J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system.
    Ezziddin S; Adler L; Sabet A; Pöppel TD; Grabellus F; Yüce A; Fischer HP; Simon B; Höller T; Biersack HJ; Nagarajah J
    J Nucl Med; 2014 Aug; 55(8):1260-6. PubMed ID: 24876204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients.
    Johnbeck CB; Knigge U; Langer SW; Loft A; Berthelsen AK; Federspiel B; Binderup T; Kjaer A
    J Nucl Med; 2016 Dec; 57(12):1851-1857. PubMed ID: 27469355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
    Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
    J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
    J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma.
    Hyun SH; Choi JY; Shim YM; Kim K; Lee SJ; Cho YS; Lee JY; Lee KH; Kim BT
    Ann Surg Oncol; 2010 Jan; 17(1):115-22. PubMed ID: 19826877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor.
    Sharma P; Naswa N; Kc SS; Alvarado LA; Dwivedi AK; Yadav Y; Kumar R; Ammini AC; Bal C
    Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2194-202. PubMed ID: 25030618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors.
    Tomimaru Y; Eguchi H; Tatsumi M; Kim T; Hama N; Wada H; Kawamoto K; Kobayashi S; Morii E; Mori M; Doki Y; Nagano H
    Surgery; 2015 Feb; 157(2):269-76. PubMed ID: 25311263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients.
    Pryma DA; Schöder H; Gönen M; Robbins RJ; Larson SM; Yeung HW
    J Nucl Med; 2006 Aug; 47(8):1260-6. PubMed ID: 16883003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Usefulness of
    Rinzivillo M; Partelli S; Prosperi D; Capurso G; Pizzichini P; Iannicelli E; Merola E; Muffatti F; Scopinaro F; Schillaci O; Salgarello M; Falconi M; Delle Fave G; Panzuto F
    Oncologist; 2018 Feb; 23(2):186-192. PubMed ID: 29118267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definitive chemo-radiotherapy for squamous cell carcinoma of the pharynx: impact of baseline low hemoglobin level (<12 g/dL) and post-radiation therapy F-18 FDG-PET/CT.
    Katahira-Suzuki R; Hata M; Tateishi U; Taguchi T; Takano S; Omura-Minamisawa M; Inoue T
    Ann Nucl Med; 2015 Jan; 29(1):37-45. PubMed ID: 25228378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG PET/CT and nestin expression as prognostic tools in pulmonary neuroendocrine tumours.
    Bromińska B; Czepczyński R; Gabryel P; Jarmołowska-Jurczyszyn D; Janicka-Jedyńska M; Sawicka-Gutaj N; Gut P; Bromiński G; Dyszkiewicz W; Ruchała M
    Nucl Med Commun; 2019 Apr; 40(4):353-360. PubMed ID: 30640182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of FDG uptake in early stage non-small cell lung cancer.
    Hanin FX; Lonneux M; Cornet J; Noirhomme P; Coulon C; Distexhe J; Poncelet AJ
    Eur J Cardiothorac Surg; 2008 May; 33(5):819-23. PubMed ID: 18374589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma.
    Lee JW; Paeng JC; Kang KW; Kwon HW; Suh KS; Chung JK; Lee MC; Lee DS
    J Nucl Med; 2009 May; 50(5):682-7. PubMed ID: 19372474
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Binderup T; Knigge U; Johnbeck CB; Loft A; Berthelsen AK; Oturai P; Mortensen J; Federspiel B; Langer SW; Kjaer A
    J Nucl Med; 2021 Jun; 62(6):808-815. PubMed ID: 33067340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lesion-by-lesion correlation between uptake at FDG PET and the Ki67 proliferation index in resected pancreatic neuroendocrine tumors.
    de Mestier L; Armani M; Cros J; Hentic O; Rebours V; Cadiot G; Sauvanet A; Couvelard A; Lebtahi R; Ruszniewski P
    Dig Liver Dis; 2019 Dec; 51(12):1720-1724. PubMed ID: 31350186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive prognostic value of local and distant recurrence of F-fluorodeoxyglucose positron emission tomography for pancreatic neuroendocrine tumors with reference to World Health Organization classifications (2004, 2010). Case series study.
    Durán HJ; Ielpo B; Díaz E; Fabra I; Caruso R; Malavé L; Cano-Valderrama O; Garcia L; Quijano Y; Vicente E
    Int J Surg; 2016 May; 29():176-82. PubMed ID: 27063856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.